Ongoing and Future Clinical Trials of Pharmacotherapy for Heart Failure.
Journal
American journal of cardiovascular drugs : drugs, devices, and other interventions
ISSN: 1179-187X
Titre abrégé: Am J Cardiovasc Drugs
Pays: New Zealand
ID NLM: 100967755
Informations de publication
Date de publication:
22 Jun 2024
22 Jun 2024
Historique:
accepted:
30
05
2024
medline:
22
6
2024
pubmed:
22
6
2024
entrez:
22
6
2024
Statut:
aheadofprint
Résumé
Increasing knowledge of the processes leading to heart failure (HF) has allowed significant developments in therapies for HF over the past few decades. Despite the evolution of HF treatment, it still places a large burden on patients and health care systems across the world.We used clinicaltrials.gov to gather information about clinical trials as of August 2023 studying pharmacotherapy for HF. We included interventional trials that were "active, not recruiting", "recruiting", or looking for participants but "not yet recruiting". In total, 119 studies met our criteria of ongoing clinical trials studying novel as well as currently approved HF pharmacotherapies. The major interventions were novel medications/already approved medications for other diseases 29 % (34 trials), sodium-glucose co-transporter inhibitors 21 % (25 trials), angiotensin receptor blocker-neprilysin inhibitors 10 % (12 trials), diuretics 14 % (17 trials) and mineralocorticoid receptor antagonists 5 % (6 trials). Ongoing research will aid in reducing the impact of HF and we summarize clinical trials leading the way to better HF treatment in this review.
Identifiants
pubmed: 38907865
doi: 10.1007/s40256-024-00658-0
pii: 10.1007/s40256-024-00658-0
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Ugene E, Raunwald B. Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997;337:1360–9. https://doi.org/10.1056/NEJM199711063371906 .
doi: 10.1056/NEJM199711063371906
Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res. 2021;128:1421–34.
doi: 10.1161/CIRCRESAHA.121.318172
pubmed: 33983838
Sayed A, Abramov D, Fonarow GC, Mamas MA, Kobo O, Butler J, et al. Reversals in the decline of heart failure mortality in the US, 1999–2021. JAMA Cardiol. 2024;9:585.
doi: 10.1001/jamacardio.2024.0615
pubmed: 38656398
Bozkurt B, Ahmad T, Alexander KM, Baker WL, Bosak K, Breathett K, et al. Heart failure epidemiology and outcomes statistics: a report of the heart failure society of America. J Card Fail. 2023;29:1412–51.
doi: 10.1016/j.cardfail.2023.07.006
pubmed: 37797885
pmcid: 10864030
Carluccio E, Dini FL, Bitto R, Ciccarelli M, Correale M, D’Agostino A, et al. Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: an echocardiographic study. Int J Cardiol. 2022;350:62–8.
doi: 10.1016/j.ijcard.2022.01.004
pubmed: 34998946
Donal E, L’official G, Kosmala W. New guidelines for managing chronic heart failure patients and new needs in echocardiography. Int J Cardiol. 2022;353:71–2.
doi: 10.1016/j.ijcard.2022.01.035
pubmed: 35074493
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145:E895-1032.
pubmed: 35363499
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413–24. https://doi.org/10.1056/NEJMoa2022190 .
doi: 10.1056/NEJMoa2022190
pubmed: 32865377
Borlaug BA, Sharma K, Shah SJ, Ho JE. Heart failure with preserved ejection fraction: JACC scientific statement. J Am Coll Cardiol. 2023;81:1810–34.
doi: 10.1016/j.jacc.2023.01.049
pubmed: 37137592
McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995–2008. https://doi.org/10.1056/NEJMoa1911303 .
doi: 10.1056/NEJMoa1911303
pubmed: 31535829
Miller AB. Aldosterone antagonism in heart failure. Vasc Health Risk Manag. 2007;3:605.
pubmed: 18078011
pmcid: 2291304
Whittaker A, Kragh ÅM, Hartleib-Geschwindner J, Albayaty M, Backlund A, Greasley PJ, et al. Safety, tolerability, and pharmacokinetics of the mineralocorticoid receptor modulator AZD9977 in healthy men: a phase i multiple ascending dose study. Clin Transl Sci. 2020;13:275–83.
doi: 10.1111/cts.12705
pubmed: 31584739
Gupta R, Testani J, Collins S. Diuretic resistance in heart failure. Curr Heart Fail Rep. 2019;16:57–66.
doi: 10.1007/s11897-019-0424-1
pubmed: 30762178
pmcid: 6431570
Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, et al. Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med. 2022;387:1185–95.
doi: 10.1056/NEJMoa2203094
pubmed: 36027559
Felker GM. New decongestion strategies in an evolving heart failure landscape. N Engl J Med. 2022;387:1231–3. https://doi.org/10.1056/NEJMe2209997 .
doi: 10.1056/NEJMe2209997
pubmed: 36027571
Halatchev IG, Wu WC, Heidenreich PA, Djukic E, Balasubramanian S, Ohlms KB, et al. Inpatient versus outpatient intravenous diuresis for the acute exacerbation of chronic heart failure. Int J Cardiol Heart Vasc. 2021;36: 100860.
pubmed: 34485679
pmcid: 8391052
Skali H, Dwyer EM, Goldstein R, Haigney M, Krone R, Kukin M, et al. Prognosis and response to therapy of first inpatient and outpatient heart failure event in a heart failure clinical trial: MADIT-CRT. Eur J Heart Fail. 2014;16:560–5.
doi: 10.1002/ejhf.71
pubmed: 24578164
Jiang WL, Gu HB, Zhang YF, Xia QQ, Qi J, Chen JC. Vitamin D supplementation in the treatment of chronic heart failure: a meta-analysis of randomized controlled trials. Clin Cardiol. 2016;39:56–61.
doi: 10.1002/clc.22473
pubmed: 26415519
Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83:754–9.
doi: 10.1093/ajcn/83.4.754
pubmed: 16600924
Coratelli P, Petrarulo F, Buongiorno E, Giannattasio M, Antonelli G, Amerio A. Improvement in left ventricular function during treatment of hemodialysis patients with 25-OHD3. Contrib Nephrol. 1984;41:433–7.
doi: 10.1159/000429325
pubmed: 6549286
Nielsen R, Møller N, Gormsen LC, Tolbod LP, Hansson NH, Sorensen J, et al. Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients. Circulation. 2019;139:2129–41.
doi: 10.1161/CIRCULATIONAHA.118.036459
pubmed: 30884964
pmcid: 6493702
Banerjee S, Mwangi JG, Stanley TK, Mitra R, Ebong EE. Regeneration and assessment of the endothelial glycocalyx to address cardiovascular disease. Ind Eng Chem Res. 2021;60:17328–47.
doi: 10.1021/acs.iecr.1c03074
Fukaya E, Gloviczki ML. An introduction to endothelial glycocalyx-what is it and why does it matter?
The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–33. https://pubmed.ncbi.nlm.nih.gov/9036306/ . Cited 22 Apr 2024.
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA. 2007;298:1180–8.
doi: 10.1001/jama.298.10.1180
pubmed: 17848652
Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, et al. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med. 2016;374:1321–31.
doi: 10.1056/NEJMoa1506930
pubmed: 26886418
pmcid: 4887756
Benes J, Kotrc M, Kroupova K, Wohlfahrt P, Kovar J, Franekova J, et al. Metformin treatment is associated with improved outcome in patients with diabetes and advanced heart failure (HFrEF). Sci Rep. 2022;12: 13038.
doi: 10.1038/s41598-022-17327-4
pubmed: 35906276
pmcid: 9338272
Jyothirmayi GN, Soni BJ, Masurekar M, Lyons M, Regan TJ. Effects of metformin on collagen glycation and diastolic dysfunction in diabetic myocardium. J Cardiovasc Pharmacol Therap. 1998;3:319–26. https://doi.org/10.1177/107424849800300407 .
doi: 10.1177/107424849800300407
Halabi A, Sen J, Huynh Q, Marwick TH. Metformin treatment in heart failure with preserved ejection fraction: a systematic review and meta-regression analysis. Cardiovasc Diabetol. 2020;19:01100.
doi: 10.1186/s12933-020-01100-w
Sasayama S, Izumi T, Seino Y, Ueshima K, Asanoi H. Effects of nocturnal oxygen therapy on outcome measures in patients with chronic heart failure and cheyne-stokes respiration. Circ J. 2006;70:1–7.
doi: 10.1253/circj.70.1
pubmed: 16377916
Woessner MN, Neil C, Saner NJ, Goodman CA, McIlvenna LC, De Zevallos JO, et al. Effect of inorganic nitrate on exercise capacity, mitochondria respiration, and vascular function in heart failure with reduced ejection fraction. J Appl Physiol. 2020;128:1355–64.
doi: 10.1152/japplphysiol.00850.2019
pubmed: 32240013
Hirai DM, Zelt JT, Jones JH, Castanhas LG, Bentley RF, Earle W, et al. Dietary nitrate supplementation and exercise tolerance in patients with heart failure with reduced ejection fraction. Am J Physiol Regul Integr Comp Physiol. 2017;312:R13-22.
doi: 10.1152/ajpregu.00263.2016
pubmed: 27784687
Kansakar U, Varzideh F, Jankauskas SS, Gambardella J, Trimarco B, Santulli G. Advances in the understanding of excitation-contraction coupling: the pulsing quest for drugs against heart failure and arrhythmias. Eur Heart J Cardiovasc Pharmacother. 2021;7: e91.
doi: 10.1093/ehjcvp/pvab069
pubmed: 34498676
pmcid: 9034200
PW A, B P, KJ A, J E, AF H, J B, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020;382. https://pubmed.ncbi.nlm.nih.gov/32222134/ . Cited 22 Apr 2024.
Barratt J, Andric B, Tataradze A, Schömig M, Reusch M, Valluri U, et al. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a phase 3, randomized, open-label, active-controlled study (DOLOMITES). Nephrol Dial Transplant. 2021;36:1616–28.
doi: 10.1093/ndt/gfab191
pubmed: 34077510
pmcid: 8396401
Verdino P, Lee SL, Cooper FN, Cottle SR, Grealish PF, Hu CC, et al. Development of a long-acting relaxin analogue, LY3540378, for treatment of chronic heart failure. Br J Pharmacol. 2023;180:1965–80.
doi: 10.1111/bph.16055
pubmed: 36780899
Batkai S, Genschel C, Viereck J, Rump S, Bär C, Borchert T, et al. CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure. Eur Heart J. 2021;42:192.
doi: 10.1093/eurheartj/ehaa791
pubmed: 33089304
Nieminen M, Fruhwald S, Heart LH-, and lung, 2013 undefined. Levosimendan: current data, clinical use and future development. ncbi.nlm.nih.govMS Nieminen, S Fruhwald, LMA Heunks, PK Suominen, AC Gordon, M Kivikko, P PolleselloHeart, lung and vessels, 2013 ncbi.nlm.nih.gov [Internet]. [cited 2024 Apr 22]; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868185/ . Cited 22 Apr 2024.
Kida K, Miyajima I, Suzuki N, Greenberg BH, Akashi YJ. Nutritional management of heart failure. J Cardiol. 2023;81:283–91.
doi: 10.1016/j.jjcc.2022.11.001
pubmed: 36370995
Abdin A, Anker SD, Butler J, Coats AJS, Kindermann I, Lainscak M, et al. “Time is prognosis” in heart failure: time-to-treatment initiation as a modifiable risk factor. ESC Heart Fail. 2021;8:4444–53.
doi: 10.1002/ehf2.13646
pubmed: 34655282
pmcid: 8712849
Greene SJ, Bauersachs J, Brugts JJ, Ezekowitz JA, Lam CSP, Lund LH, et al. Worsening heart failure: nomenclature, epidemiology, and future directions: JACC review topic of the week. J Am Coll Cardiol. 2023;81:413–24.
doi: 10.1016/j.jacc.2022.11.023
pubmed: 36697141
Lopaschuk GD, Verma S. Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review. JACC Basic Transl Sci. 2020;5:632.
doi: 10.1016/j.jacbts.2020.02.004
pubmed: 32613148
pmcid: 7315190
Ferhatbegović L, Mršić D, Macić-Džanković A. The benefits of GLP1 receptors in cardiovascular diseases. Front Clin Diabetes Health care. 2023;4: 1293926.
doi: 10.3389/fcdhc.2023.1293926